Abstract
Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor. After 5 days of daily treatment, the tremor was reduced by 60%. Diltiazem and verapamil which act on different calcium channels had no such effect. Ethosuximide also potentiated the anti-tremor effect of the dopamine D2 agonist LY-171555.
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Diltiazem / administration & dosage
-
Dopamine Agents / administration & dosage
-
Dose-Response Relationship, Drug
-
Electromyography / drug effects
-
Ergolines / administration & dosage
-
Ethosuximide / administration & dosage*
-
Ethosuximide / toxicity
-
Female
-
Macaca fascicularis
-
Neurologic Examination / drug effects
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy*
-
Quinpirole
-
Tremor / chemically induced
-
Tremor / drug therapy
-
Verapamil / administration & dosage
Substances
-
Dopamine Agents
-
Ergolines
-
Quinpirole
-
Ethosuximide
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Verapamil
-
Diltiazem